Diabetes

Top Story

DEVOTE: Insulin degludec demonstrates CV safety, reduced risk for severe hypoglycemia

DEVOTE: Insulin degludec demonstrates CV safety, reduced risk for severe hypoglycemia
June 21, 2017

SAN DIEGO — In the DEVOTE cardiovascular outcomes trial, insulin degludec was noninferior to insulin glargine for the primary endpoint of major adverse cardiovascular events and was associated with significant reductions in severe hypoglycemia among high-risk patients with type 2 diabetes.

The randomized, double blind, treat-to-target, event-driven, CV outcomes trial included 7,637 patients with type 2 diabetes enrolled at 436 sites in 20 countries between October 2013 and November 2014. Researchers randomly assigned 3,818 patients to receive insulin degludec 100 U/mL (Tresiba, Novo Nordisk), a new-generation, ultra-long-acting basal insulin, and 3,819 to receive insulin glargine U100 (Lantus, Sanofi), a first-generation insulin, once per day between dinner and bedtime.

Perspective

FDA committee supports expanded CV indication for liraglutide in adults with type 2 diabetes

June 20, 2017
An FDA advisory panel on Tuesday voted 17 to 2 in favor of an expanded indication for the GLP-1 receptor agonist liraglutide, supporting language in the prescribing…
In the Journals

Select traditional Chinese medicine may benefit patients with heart disease

June 16, 2017
Unmet needs in Western medicine have made traditional Chinese medicine a more common alternative for primary and secondary CVD prevention, but more randomized trials of…
Meeting News

Long-term metformin therapy reduces CVD risk in type 1 diabetes

June 15, 2017
SAN DIEGO — Middle-aged adults with long-standing type 1 diabetes at high risk for cardiovascular disease who added metformin to insulin therapy for 3 years saw…
Meeting News

DEVOTE: Insulin degludec demonstrates CV safety, reduced risk for severe hypoglycemia

June 21, 2017
SAN DIEGO — In the DEVOTE cardiovascular outcomes trial, insulin degludec was noninferior to insulin glargine for the primary endpoint of major…

Perspective

FDA committee supports expanded CV indication for liraglutide in adults with type 2 diabetes

June 20, 2017
An FDA advisory panel on Tuesday voted 17 to 2 in favor of an expanded indication for the GLP-1 receptor agonist liraglutide, supporting language in…

In the Journals

Select traditional Chinese medicine may benefit patients with heart disease

June 16, 2017
Unmet needs in Western medicine have made traditional Chinese medicine a more common alternative for primary and secondary CVD prevention, but more…

Meeting News

Long-term metformin therapy reduces CVD risk in type 1 diabetes

June 15, 2017
SAN DIEGO — Middle-aged adults with long-standing type 1 diabetes at high risk for cardiovascular disease who added metformin to insulin…

Meeting News

CVD-REAL: SGLT2 inhibitors benefit patients with diabetes, irrespective of CV history

June 14, 2017
SAN DIEGO — Treatment with an SGLT2 inhibitor was associated with lower rates of death and heart failure compared with other glucose-lowering…

Meeting News

Canagliflozin reduces risk for CVD, kidney disease in patients with type 2 diabetes

June 12, 2017
SAN DIEGO — Patients with type 2 diabetes at high risk for cardiovascular disease assigned the SGLT2 inhibitor canagliflozin saw a 33%…

In the Journals

Glycemic measures may not be accurate for black patients

June 12, 2017
Hemoglobin A1c levels may misjudge the mean glucose concentration in black patients with type 1 diabetes possibly because of racial differences in…

Meeting News

LEADER: Baseline CVD medication use does not explain liraglutide CV benefit

June 12, 2017
SAN DIEGO — Further analyses of results from the LEADER trial revealed that baseline HbA1c, cardiovascular medication use and…

Meeting News

PCSK9 inhibitor lowers CV risk in insulin-treated type 2 diabetes

June 11, 2017
SAN DIEGO — Results of the ODYSSEY DM-INSULIN trial indicate that adults with dyslipidemia and type 2 diabetes who are taking insulin can…

Meeting News

Uromodulin shows promise for risk stratification, prediction of kidney disease and atherosclerosis

June 11, 2017
SAN DIEGO — In a new study, serum uromodulin levels were strongly associated with risk for incident diabetic kidney disease and coronary…

More Headlines »
Advertisement
Advertisement